Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
postpartum depression
Biotech
Sage lays off 40%, shakes up C-suite to get zuranolone to market
Sage will jettison 40% of staff as it navigates a future for its Biogen-partnered drug after the therapy was rejected for major depressive disorder.
James Waldron
Aug 31, 2023 7:44am
Biogen's tight-lipped zuranolone remarks disquiet Sage investors
Jul 26, 2023 10:45am
Biogen and Sage get August PDUFA date for oral depression drug
Feb 6, 2023 8:15am
JPM23: Sage CEO says postpartum depression is no niche market
Jan 10, 2023 3:47pm
Sage, Biogen post depression data as FDA filing nears completion
Oct 17, 2022 8:01am
SKYLARK sings: Sage, Biogen hatch positive phase 3 data in PPD
Jun 1, 2022 8:05am
